What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Lung cancer, Oncology, Chemotherapy and Surgery.
His research in Hazard ratio, Docetaxel, Clinical endpoint, Bevacizumab and Survival rate are components of Internal medicine.
Martin Reck has researched Lung cancer in several fields, including Clinical trial, Phases of clinical research, Epidermal growth factor receptor, Carboplatin and Ipilimumab.
His studies deal with areas such as Interim analysis, Paclitaxel, Atezolizumab and Etoposide as well as Carboplatin.
His Oncology study integrates concerns from other disciplines, such as Cancer, Cisplatin, Randomized controlled trial, Carcinoma and Nivolumab.
His Chemotherapy research incorporates elements of Pembrolizumab and Necitumumab.
His most cited work include:
- Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer (4746 citations)
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (4177 citations)
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (1938 citations)
What are the main themes of his work throughout his whole career to date?
Martin Reck mainly investigates Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery.
Docetaxel, Carboplatin, Pemetrexed, Nivolumab and Phases of clinical research are subfields of Internal medicine in which his conducts study.
His Docetaxel research incorporates elements of Ramucirumab and Adenocarcinoma.
His work carried out in the field of Oncology brings together such families of science as Bevacizumab and Clinical trial.
He combines subjects such as Cancer research, Adverse effect, Epidermal growth factor receptor and Hazard ratio with his study of Lung cancer.
His Chemotherapy research is multidisciplinary, incorporating perspectives in Pembrolizumab, Cancer, Atezolizumab, Immunotherapy and First line.
He most often published in these fields:
- Internal medicine (79.75%)
- Oncology (68.10%)
- Lung cancer (54.94%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (79.75%)
- Oncology (68.10%)
- Lung cancer (54.94%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Lung cancer, Chemotherapy and Pembrolizumab.
His studies in Atezolizumab, Nivolumab, Carboplatin, Bevacizumab and Pemetrexed are all subfields of Internal medicine research.
His biological study deals with issues like Ipilimumab, which deal with fields such as Checkmate.
Martin Reck has researched Oncology in several fields, including Clinical trial, Docetaxel and Immunotherapy.
His Lung cancer study combines topics from a wide range of disciplines, such as Cancer, Ramucirumab, Clinical endpoint, Carcinoma and Hazard ratio.
The Chemotherapy study combines topics in areas such as Immune system, Immune checkpoint inhibitors and First line.
Between 2017 and 2021, his most popular works were:
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (1938 citations)
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (1302 citations)
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC (1154 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Martin Reck focuses on Internal medicine, Lung cancer, Oncology, Chemotherapy and Nivolumab.
His work on Non small cell as part of general Lung cancer research is frequently linked to Response Evaluation Criteria in Solid Tumors, bridging the gap between disciplines.
His Oncology study incorporates themes from Immunotherapy, Carcinoma, Docetaxel and Atezolizumab.
His study focuses on the intersection of Chemotherapy and fields such as Overall survival with connections in the field of Paclitaxel, Immunosuppression and VEGF receptors.
His work is dedicated to discovering how Nivolumab, Ipilimumab are connected with Checkmate and other disciplines.
The various areas that Martin Reck examines in his Carboplatin study include Etoposide and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
